Research tools
Fecal calprotectin articles covering stool inflammation testing, flare monitoring, treatment response, and IBD research. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
16 articles
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Perianal abscesses or fistulas in children can be an early sign of Crohn's disease. Recognizing which kids are at higher risk helps guide follow-up and testing so diagnosis isn't delayed.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....
Fatigue is a common, often persistent symptom in Crohn’s disease even during remission. This study suggests brain structure differences may be linked to fatigue when inflammation is low, pointing to potential...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary...
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...
Diet is a modifiable factor that may influence inflammation and the gut microbiome. If the Mediterranean diet is linked with lower disease activity and inflammatory markers in newly diagnosed Crohn’s disease, patients...
If you have Crohn’s disease, this study suggests following a Mediterranean-style diet may be linked with lower inflammation and a gentler disease course, and it could positively change the gut microbiome and metabolites.
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
